drugset / Trial / NCT05863845

Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCL

NCT05863845

Unknown 52 enrolled Ruijin Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

This single-center, randomized clinical study will evaluate the efficacy and safety of Venetoclax combined with BEAM Pretreatment Regimen in ASCT treatment of DLBCL patients.

Timeline

Start
2023-06-01
Primary completion
2024-11-30
Completion
2025-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Venetoclax Small molecule 800 mg Oral
Background Cytarabine Small molecule 100 mg/m2 Intravenous
Background Etoposide Small molecule 200 mg/m2 Intravenous
Background Melphalan Small molecule 140 mg/m2 Intravenous
Background carmustine Small molecule 300 mg/m2 Intravenous